LivaNova (LIVN) Downgraded by BidaskClub to Buy
BidaskClub downgraded shares of LivaNova (NASDAQ:LIVN) from a strong-buy rating to a buy rating in a report published on Tuesday.
A number of other brokerages also recently weighed in on LIVN. ValuEngine raised shares of LivaNova from a hold rating to a buy rating in a report on Thursday, November 2nd. WBB Securities lowered shares of LivaNova from a hold rating to a sell rating and set a $50.00 price objective for the company. in a research note on Tuesday, August 15th. Canaccord Genuity reaffirmed a hold rating and set a $76.00 price objective on shares of LivaNova in a research note on Tuesday, December 5th. Piper Jaffray Companies reaffirmed an overweight rating and set a $75.00 price objective on shares of LivaNova in a research note on Tuesday, September 12th. Finally, Needham & Company LLC upped their price objective on shares of LivaNova from $93.00 to $97.00 and gave the company a buy rating in a research note on Tuesday, December 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $79.71.
Shares of LivaNova (LIVN) opened at $81.70 on Tuesday. LivaNova has a 1-year low of $44.58 and a 1-year high of $88.56. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.03 and a quick ratio of 1.42. The firm has a market cap of $3,981.31, a PE ratio of 23.80, a price-to-earnings-growth ratio of 2.48 and a beta of 0.61.
In related news, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $74.58, for a total value of $74,580.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Hugh M. Morrison sold 1,830 shares of the stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $88.00, for a total value of $161,040.00. The disclosure for this sale can be found here. Insiders sold 6,830 shares of company stock valued at $557,100 over the last three months. 0.28% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in LIVN. PNC Financial Services Group Inc. increased its holdings in LivaNova by 9.8% in the second quarter. PNC Financial Services Group Inc. now owns 1,707 shares of the company’s stock worth $105,000 after buying an additional 153 shares during the last quarter. Riverhead Capital Management LLC increased its holdings in LivaNova by 76.3% in the second quarter. Riverhead Capital Management LLC now owns 1,763 shares of the company’s stock worth $108,000 after buying an additional 763 shares during the last quarter. Teacher Retirement System of Texas acquired a new position in LivaNova in the second quarter worth approximately $204,000. Shelton Capital Management acquired a new position in LivaNova during the third quarter valued at approximately $209,000. Finally, Bessemer Group Inc. acquired a new position in LivaNova during the second quarter valued at approximately $220,000. Hedge funds and other institutional investors own 86.07% of the company’s stock.
TRADEMARK VIOLATION WARNING: “LivaNova (LIVN) Downgraded by BidaskClub to Buy” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/12/13/livanova-livn-downgraded-by-bidaskclub-to-buy.html.
LivaNova Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Stock Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related stocks with our FREE daily email newsletter.